Understanding how AMPK affects heart damage from a common cancer drug
Deciphering the Role of AMPK in Doxorubicin Cardiotoxicity
This study is looking at how a protein called AMPK might help protect the heart from damage caused by a common cancer drug, doxorubicin, while still allowing the drug to work effectively against cancer, so that patients can have safer treatment options.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York Inst of Technology NIH-funded |
| Lab location | 1 site (Old Westbury, United States) |
| Project ID | NIH-10580326 on NIH RePORTER |
What this research studies
This research investigates the role of AMP-activated protein kinase (AMPK) in reducing heart damage caused by doxorubicin, a widely used cancer treatment. The study aims to identify whether activating AMPK can protect the heart without reducing the drug's effectiveness against cancer. Researchers will use both cell-based studies and animal models to explore how different AMPK isoforms influence doxorubicin's cardiotoxic effects. By understanding these mechanisms, the research seeks to find ways to improve the safety of cancer treatments for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are being treated with doxorubicin and are at risk of heart complications.
Not a fit: Patients who are not receiving doxorubicin or those with pre-existing severe heart conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer cancer treatments that minimize heart damage for patients receiving doxorubicin.
How similar studies have performed: Previous studies have shown promise in using AMPK activation to mitigate drug-induced cardiotoxicity, suggesting potential for success in this approach.
Where this research is happening
Old Westbury, United States
- New York Inst of Technology — Old Westbury, United States (Active)
Researchers
- Principal investigator: Liang, Qiangrong — New York Inst of Technology
- Study coordinator: Liang, Qiangrong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.